Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;140(7):1109-1120.
doi: 10.1007/s00439-021-02283-2. Epub 2021 May 4.

Missense and truncating variants in CHD5 in a dominant neurodevelopmental disorder with intellectual disability, behavioral disturbances, and epilepsy

Ilaria Parenti #  1 , Daphné Lehalle #  2 , Caroline Nava  3 , Erin Torti  4 , Elsa Leitão  1 , Richard Person  4 , Takeshi Mizuguchi  5 , Naomichi Matsumoto  5 , Mitsuhiro Kato  6 , Kazuyuki Nakamura  7 , Stella A de Man  8 , Heidi Cope  9 , Vandana Shashi  9 ; Undiagnosed Diseases Network; Jennifer Friedman  10 , Pascal Joset  11   12 , Katharina Steindl  11   12 , Anita Rauch  11   12 , Irena Muffels  13 , Peter M van Hasselt  13 , Florence Petit  14 , Thomas Smol  15 , Gwenaël Le Guyader  16   17 , Frédéric Bilan  16   17 , Arthur Sorlin  18   19   20 , Antonio Vitobello  18   19 , Christophe Philippe  18   19 , Ingrid M B H van de Laar  21 , Marjon A van Slegtenhorst  21 , Philippe M Campeau  22   23 , Ping Yee Billie Au  24 , Mitsuko Nakashima  25 , Hirotomo Saitsu  25 , Tatsuya Yamamoto  26 , Yumiko Nomura  27   28 , Raymond J Louie  29 , Michael J Lyons  29 , Amy Dobson  29 , Astrid S Plomp  30 , M Mahdi Motazacker  31 , Frank J Kaiser  1 , Andrew T Timberlake  32 , Sabine A Fuchs  13 , Christel Depienne #  33   34 , Cyril Mignot #  35   36
Affiliations

Missense and truncating variants in CHD5 in a dominant neurodevelopmental disorder with intellectual disability, behavioral disturbances, and epilepsy

Ilaria Parenti et al. Hum Genet. 2021 Jul.

Abstract

Located in the critical 1p36 microdeletion region, the chromodomain helicase DNA-binding protein 5 (CHD5) gene encodes a subunit of the nucleosome remodeling and deacetylation (NuRD) complex required for neuronal development. Pathogenic variants in six of nine chromodomain (CHD) genes cause autosomal dominant neurodevelopmental disorders, while CHD5-related disorders are still unknown. Thanks to GeneMatcher and international collaborations, we assembled a cohort of 16 unrelated individuals harboring heterozygous CHD5 variants, all identified by exome sequencing. Twelve patients had de novo CHD5 variants, including ten missense and two splice site variants. Three familial cases had nonsense or missense variants segregating with speech delay, learning disabilities, and/or craniosynostosis. One patient carried a frameshift variant of unknown inheritance due to unavailability of the father. The most common clinical features included language deficits (81%), behavioral symptoms (69%), intellectual disability (64%), epilepsy (62%), and motor delay (56%). Epilepsy types were variable, with West syndrome observed in three patients, generalized tonic-clonic seizures in two, and other subtypes observed in one individual each. Our findings suggest that, in line with other CHD-related disorders, heterozygous CHD5 variants are associated with a variable neurodevelopmental syndrome that includes intellectual disability with speech delay, epilepsy, and behavioral problems as main features.

PubMed Disclaimer

Conflict of interest statement

Dr. Louie is a clinical laboratory director in molecular genetics and the Greenwood Genetic Center receives fee income from clinical laboratory testing. Erin Torti and Richard Person are employees of GeneDx, Inc. All other authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Family trees of the inherited mutations. In family 1, Individual III-3 corresponds to Patient 1. In family 2, Individual III-1 corresponds to Patient 4. In family 3, Individual III-1 corresponds to Patient 6. The variants in CHD5 identified in these three families are associated with incomplete penetrance and variable expressivity
Fig. 2
Fig. 2
Distribution of the CHD5 variants based on position and conservation of the affected amino acids. a Schematic representation of the CHD5 protein and its domains, with position of the identified mutations relative to exon and domain distribution. The CHDNT domain is indicated in yellow, the PHD domains in red, the Chd domains in green, the helicase domains in light blue, the DUFs domains in purple, and the CHDCT2 domain in lilac. Inherited variants are indicated in blue and de novo variants in black. Putative loss-of-function variants are indicated with a triangle, likely pathogenic missense substitutions with a filled circle and the VUS with an empty circle. b Comparison of the distribution of the variants identified in our cohort with the synonymous and missense variants reported in gnomAD, with relative position of each affected CHD5 residue across the protein domains. c Comparison of a portion of the highly conserved C-terminal Helicase domain among yeast SNF2 (black) and human CHD3 (red), CHD4 (green), and CHD5 (blue). Pathogenic missense substitutions altering residues in this domain are indicated with the color corresponding to the CHD protein where the variant was identified. The amino acids altered by the substitutions are indicated with a square whose color corresponds to the CHD protein where the variant was identified
Fig. 3
Fig. 3
Facial profiles of patients with CHD5 variants. a–c Patient 1 age 6 months. d, e Patient 2 age 11 years 4 months. f Patient 4 age 1 year. g, h Patient 7 age 24 years. i, j Patient 10 age 3 (i) and 5 years (j). k–n Patient 13 age 9 months (k), 9 years (l) and 22 years (m, n). o, p Patient 14 age 3 years six months (o) and 6 years (p). Facial dysmorphism was related to craniosynostosis in Patients 1 and 4. Other patients displayed subtle facial features, such as high forehead, but no consistent facial dysmorphism emerges from the whole panel
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–249. doi: 10.1038/nmeth0410-248. - DOI - PMC - PubMed
    1. Bagchi A, Papazoglu C, Wu Y, et al. CHD5 is a tumor suppressor at human 1p36. Cell. 2007;128:459–475. doi: 10.1016/j.cell.2006.11.052. - DOI - PubMed
    1. Bishop B, Ho KK, Tyler K, et al. The chromatin remodeler chd5 is necessary for proper head development during embryogenesis of Danio rerio. Biochimica et Biophysica Acta (BBA) Gene Regul Mech. 2015;189:1040–1050. doi: 10.1016/j.bbagrm.2015.06.006. - DOI - PMC - PubMed
    1. Carlston CM, O’Donnell-Luria AH, Underhill HR, et al. Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome. Hum Mutat. 2017 doi: 10.1002/humu.23203. - DOI - PMC - PubMed
    1. Chen J, Zhang J, Liu A, et al. CHD2-related epilepsy: novel mutations and new phenotypes. Dev Med Child Neurol. 2020;62:647–653. doi: 10.1111/dmcn.14367. - DOI - PubMed
-